Tokyo - Delayed Quote JPY

Cytori Cell Research Institute, Inc. (3750.T)

Compare
883.00
+1.00
+(0.11%)
At close: 3:23:36 PM GMT+9
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,560,388.00
1,560,388.00
2,144,712.00
1,335,578.00
1,388,292.00
Cost of Revenue
267,777.00
267,777.00
875,724.00
476,345.00
627,969.00
Gross Profit
1,292,611.00
1,292,611.00
1,268,988.00
859,233.00
760,322.00
Operating Expense
2,065,351.00
2,065,351.00
2,063,346.00
1,321,556.00
1,491,992.00
Operating Income
-772,740.00
-772,740.00
-794,358.00
-462,323.00
-731,670.00
Net Non Operating Interest Income Expense
-153,811.00
-153,811.00
-129,241.00
-93,194.00
-84,537.00
Pretax Income
-1,011,213.00
-1,011,213.00
-1,166,076.00
-65,336.00
-654,243.00
Tax Provision
-1,150,153.00
-1,150,153.00
-106,345.00
11,757.00
121,202.00
Net Income Common Stockholders
138,155.00
138,155.00
-1,059,941.00
-77,633.00
-831,863.00
Diluted NI Available to Com Stockholders
138,155.00
138,155.00
-1,059,941.00
-77,633.00
-831,863.00
Basic EPS
15.47
--
-118.71
-8.79
-101.64
Diluted EPS
15.42
--
-118.71
-8.79
-101.64
Basic Average Shares
8,928.38
--
8,928.55
8,829.85
8,184.40
Diluted Average Shares
8,959.47
--
8,928.55
8,829.85
8,184.40
Total Operating Income as Reported
-772,742.00
-772,742.00
-794,359.00
-462,323.00
-731,671.00
Total Expenses
2,333,128.00
2,333,128.00
2,939,070.00
1,797,901.00
2,119,961.00
Net Income from Continuing & Discontinued Operation
138,155.00
138,155.00
-1,059,941.00
-77,633.00
-831,863.00
Normalized Income
-159,927.30
-159,927.30
-773,231.56
-333,754.86
-885,540.92
Interest Expense
153,811.00
153,811.00
129,241.00
93,194.00
84,537.00
Net Interest Income
-153,811.00
-153,811.00
-129,241.00
-93,194.00
-84,537.00
EBIT
-857,402.00
-857,402.00
-1,036,835.00
27,858.00
-569,706.00
EBITDA
-603,092.00
-603,092.00
-705,344.00
348,903.00
-261,855.00
Reconciled Cost of Revenue
267,777.00
267,777.00
875,724.00
476,345.00
627,969.00
Reconciled Depreciation
254,310.00
254,310.00
331,491.00
321,045.00
307,851.00
Net Income from Continuing Operation Net Minority Interest
138,155.00
138,155.00
-1,059,941.00
-77,633.00
-831,863.00
Total Unusual Items Excluding Goodwill
388,128.00
388,128.00
-315,481.00
333,492.00
77,368.00
Total Unusual Items
388,128.00
388,128.00
-315,481.00
333,492.00
77,368.00
Normalized EBITDA
-991,220.00
-991,220.00
-389,863.00
15,411.00
-339,223.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
90,045.70
90,045.70
-28,771.56
77,370.14
23,690.08
3/31/2021 - 1/1/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ADXN Addex Therapeutics Ltd
7.31
-6.16%
 
FBIO Fortress Biotech, Inc.
1.7800
+2.30%
 
CRBU Caribou Biosciences, Inc.
1.3100
-2.24%
 
VRNA Verona Pharma plc
57.24
+4.40%
 
NWBO Northwest Biotherapeutics, Inc.
0.2700
-4.59%
 
NTLA Intellia Therapeutics, Inc.
10.51
+3.85%
 
RXRX Recursion Pharmaceuticals, Inc.
7.69
+7.40%
 
MRNA Moderna, Inc.
41.04
+0.79%